AOD-9604 vs HGH Fragment 176-191: Fat Metabolism Peptide Research Comparison (2026)

AOD-9604 vs HGH Fragment 176-191: Fat Metabolism Peptide Research Comparison (2026)

AOD-9604 and HGH Fragment 176-191 are among the most searched peptide comparisons on our platform — and for good reason: they are nearly the same compound. Understanding precisely how they differ (and when the difference matters for research design) is essential for selecting the right material.

This guide covers their structural relationship, research histories, mechanistic profiles, pricing differences, and the practical question every researcher asks: does it matter which one I order?

Quick Comparison: AOD-9604 vs HGH Fragment 176-191

The Structural Relationship: They Are Almost Identical

Human growth hormone (GH) is a 191-amino-acid protein. The C-terminal region (roughly the last 20 residues) has been identified as the lipid-metabolizing domain responsible for GH's fat-burning effects — distinct from the N-terminal region that drives IGF-1 production and anabolic effects.

HGH Fragment 176-191 is simply amino acids 176–191 of full-length GH, isolated as a standalone peptide. This fragment retains the lipolytic activity of full GH without triggering IGF-1 production, insulin resistance, or the growth-promoting effects associated with full GH use.

AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as an optimized version of Fragment 176-191. The modification is minimal but significant: an N-terminal tyrosine residue was added to the Fragment 176-191 sequence. This created a 16-amino-acid peptide (Tyr-hGH176-191) with improved bioavailability, metabolic stability, and receptor affinity compared to the unmodified fragment.

In practical terms: AOD-9604 is Fragment 176-191 with a tyrosine "cap" at the N-terminus. Both bind the same β3-adrenergic receptors to stimulate lipolysis. The tyrosine modification in AOD-9604 primarily serves pharmacokinetic purposes — resistance to enzymatic degradation and potentially improved receptor docking.

Why the "vs" Question Exists

If they're nearly identical, why do people compare them?

Three reasons:

1. Different names create confusion — Researchers, vendors, and literature may use "AOD-9604" and "Fragment 176-191" interchangeably, creating uncertainty about whether you're ordering the same compound

2. Price differential — AOD-9604's brand recognition commands a modest premium over plain Fragment 176-191

3. Clinical data asymmetry — AOD-9604 has formal clinical trial history; Fragment 176-191 primarily exists in preclinical literature

For most research applications, these compounds are functionally equivalent. The practical choice comes down to which has better COA documentation from your vendor and which fits your budget.

Mechanism of Action: Shared Biology

Both compounds exert their primary effects through β3-adrenergic receptor (β3-AR) activation:

β3-Adrenergic Pathway

The β3-adrenergic receptor is predominantly expressed in white and brown adipose tissue. Its activation triggers:

1. cAMP production via Gs-coupled signaling

2. Protein kinase A (PKA) activation

3. Hormone-sensitive lipase (HSL) phosphorylation — the rate-limiting enzyme in stored triglyceride hydrolysis

4. Triglyceride breakdown into free fatty acids and glycerol (lipolysis)

This selective mechanism is what makes Fragment 176-191 and AOD-9604 scientifically interesting: they produce lipolysis without activating the growth-promoting IGF-1 axis or disrupting glucose metabolism.

What They Do NOT Do

A key feature distinguishing both compounds from full HGH:

• •No IGF-1 elevation — confirmed in clinical studies for AOD-9604; expected for Fragment 176-191 based on structure
• •No insulin resistance — unlike full GH, which can induce transient insulin resistance at high doses
• •No tissue growth promotion — the N-terminal GH region (responsible for anabolic effects) is absent
• •No effect on bone density (positive or negative) — GH's bone effects are primarily IGF-1 mediated

This selective metabolic profile was the original rationale for developing Fragment 176-191 and then AOD-9604: to capture GH's fat-burning properties without its adverse metabolic and anabolic effects.

Research History

HGH Fragment 176-191: Preclinical Foundation

The biological activity of GH's C-terminal region was first characterized in the 1970s–1990s through work identifying which GH fragments retained lipolytic activity. Fragment 176-191 emerged as the minimal active region with preserved fat metabolism effects and no growth-promoting activity.

Key preclinical findings:

• •Dose-dependent lipolysis in adipose tissue models
• •No stimulation of IGF-1 production
• •Neutral effect on insulin sensitivity
• •Cartilage repair effects noted in some models (Ghosh et al., 2004)
• •Primarily studied in rodent and in vitro models

Fragment 176-191's research history is largely academic and preclinical, with minimal formalized clinical investigation.

AOD-9604: Clinical Development Program

AOD-9604 followed a more structured pharmaceutical development path under Metabolic Pharmaceuticals (Australia):

• •Phase I (safety): Demonstrated favorable tolerability in healthy volunteers
• •Phase II (efficacy): Moderate weight loss (~1–2 kg over 12 weeks) in obese subjects versus placebo; not dramatically superior to placebo at all doses tested
• •Phase IIb: Additional obese patient studies with oral formulations; results were mixed regarding the magnitude of weight loss, contributing to development discontinuation as an anti-obesity drug

The Phase II/IIb results were ultimately disappointing for obesity indication — AOD-9604 did not demonstrate the clinical weight loss magnitude needed for regulatory approval. However, the trial data provided substantial safety information:

• •No adverse effects on blood glucose or insulin sensitivity
• •No IGF-1 elevation confirmed in human subjects
• •Generally well-tolerated at oral and injectable doses
• •Australian TGA initially classified AOD-9604 as Schedule 4 (prescription); later classification changed

The failed obesity drug development did not diminish AOD-9604's research interest — it enhanced it, providing human safety data that pure Fragment 176-191 lacks.

Cartilage and Osteoarthritis Research

A distinct research avenue for both compounds emerged from work by Ghosh and colleagues. Studies demonstrated that Fragment 176-191 (and by extension AOD-9604) may have beneficial effects on cartilage repair and osteoarthritis, independent of the lipolytic mechanism. This included:

• •Stimulation of chondrocyte activity
• •Potential anti-inflammatory effects in articular cartilage
• •Animal model evidence for OA disease modification

This remains an active area of investigation and differentiates these compounds from pure lipolytic agents.

AOD-9604 vs Fragment 176-191: What the Evidence Favors

Dosing Protocols in Research

Both compounds share similar dosing parameters in preclinical and research settings. Clinical trial dosing from AOD-9604 studies provides reference points:

Injectable Research Protocols:

Note on Oral Formulations: AOD-9604 clinical trials included oral formulations. This is uncommon for synthetic peptides (most are degraded in the GI tract), and the oral bioavailability of Fragment 176-191 without the AOD-9604 modification is expected to be negligible. For injectable research purposes, both compounds behave equivalently.

Pricing Comparison (2026)

AOD-9604 — Market Range (2026):

HGH Fragment 176-191 — Market Range (2026):

Both compounds have 87+ combined listings on our platform. AOD-9604 commands a modest premium (15–30%) primarily due to brand recognition and the clinical trial history that researchers cite when justifying procurement. For budget-constrained protocols, Fragment 176-191 from a verified vendor offers equivalent lipolytic biology at lower cost.

→ Compare current vendor pricing: AOD-9604 Listings | Fragment 176-191 Listings

When to Choose AOD-9604

Choose AOD-9604 when:

• •Human safety data is required for your research justification or IRB documentation — clinical trial data from Metabolic Pharmaceuticals provides this
• •Oral delivery investigation is part of the protocol (AOD-9604 has the only existing oral absorption data for this peptide family)
• •Regulatory compliance research is relevant (AOD-9604's TGA history provides a regulatory framework reference)
• •Citation depth matters — more peer-reviewed publications specifically name AOD-9604
• •Budget is not a primary constraint

When to Choose HGH Fragment 176-191

Choose Fragment 176-191 when:

• •Cost efficiency is a priority for multi-dose, long-duration protocols
• •Purely preclinical lipolysis studies where the tyrosine modification is not a relevant variable
• •Cartilage/OA models where published data uses Fragment 176-191 specifically
• •Structural biology research where the exact native GH fragment sequence (without the tyrosine modification) is required for comparison to full-length GH

Can AOD-9604 and Fragment 176-191 Be Stacked?

Generally, stacking these two compounds would be redundant — they act through identical mechanisms at the same receptor. Combining them does not produce additive or synergistic effects beyond what either compound achieves at a higher individual dose.

Meaningful stacking combinations involve peptides with complementary mechanisms:

• •AOD-9604 / Fragment 176-191 + Semaglutide: GLP-1 receptor agonist adds appetite suppression and central metabolic effects to the peripheral lipolytic activity
• •AOD-9604 / Fragment 176-191 + Tesamorelin: GHRH analog increases GH production (with IGF-1 effects) while the fragment provides direct lipolysis — used in some visceral fat reduction research protocols
• •AOD-9604 / Fragment 176-191 + BPC-157 or TB-500: Recovery-focused combinations for tissue repair models that also target body composition

See our Peptide Stacking Guide for protocol considerations.

FAQ: AOD-9604 vs Fragment 176-191

Q: Are AOD-9604 and HGH Fragment 176-191 the same thing?

They are nearly identical. AOD-9604 is Fragment 176-191 with an N-terminal tyrosine residue added for improved stability and bioavailability. The core sequence and mechanism are shared. For most research purposes, they are functionally interchangeable.

Q: Does either compound increase IGF-1?

No. This is a key feature of both compounds. Neither Fragment 176-191 nor AOD-9604 activates the IGF-1 pathway. This was confirmed in human clinical trials for AOD-9604 and is expected for Fragment 176-191 based on its structural identity with the same region.

Q: Why did AOD-9604 fail clinical trials?

AOD-9604 did not fail due to safety issues — it failed to demonstrate sufficient weight loss efficacy for regulatory approval as an anti-obesity drug. The compound produced statistically significant but clinically modest weight reduction. Safety profiles were favorable. The compound remains scientifically active in research outside of obesity drug development.

Q: Does either compound affect blood sugar or insulin?

No clinically significant effects on fasting glucose or insulin sensitivity have been documented for either compound. This distinguishes them from full HGH, which can induce transient insulin resistance.

Q: Which form has better bioavailability?

AOD-9604's tyrosine modification theoretically improves metabolic stability and may enhance receptor affinity. However, for standard subcutaneous injection, the practical pharmacokinetic differences between the two forms are minimal. AOD-9604 is the only form with documented oral bioavailability data from clinical trials.

Q: What is the difference in half-life between the two?

Precise comparative half-life data is limited. AOD-9604's tyrosine modification likely confers modest resistance to proteolytic degradation, potentially extending its half-life compared to Fragment 176-191. Both are short-acting peptides requiring daily dosing for sustained effects.

Q: Can these compounds affect muscle or bone growth?

No significant anabolic (muscle-building) or bone-growth effects have been documented for either compound. The N-terminal GH region responsible for these effects (and IGF-1 stimulation) is absent in both Fragment 176-191 and AOD-9604.

Q: Is AOD-9604 still legal for research?

AOD-9604's regulatory status varies by jurisdiction. In Australia, the TGA classification has changed over time. In the US, both compounds exist in a research chemical gray area. Consult current regulatory status in your jurisdiction before procurement. All listings on Peptides.SO are for research use only.

---

Further Reading:

• •Ipamorelin vs GHRP-6: Research Comparison Guide 2026
• •CJC-1295 vs Sermorelin: Research Comparison Guide 2026
• •Melanotan I vs Melanotan II: Tanning Peptide Research Comparison Guide 2026
• •Ipamorelin vs GHRP-2: Growth Hormone Secretagogue Comparison for Researchers (2026)
• •Reconstitution Calculator
• •Peptide Stack Builder

---

AOD-9604 and HGH Fragment 176-191 are research peptides not approved for human use by any major regulatory agency. All information is provided for scientific and educational purposes only.

See also: AOD-9604 Complete Research Profile | Best Peptides for Fat Metabolism (2026) | Semaglutide vs Tirzepatide Comparison